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 خصائص ومعدل انتشار التهاب الكبد الوبائي املزمن ج
مبركز رعاية ثالثية يف عمان
�صعيد البو�صايف، حليمة ال�صعيلية، هبة عمر، هيفا الزهيبية، جي�صيالن، خالد النعماين
abstract: Objectives: Chronic hepatitis C (CHC) is a leading cause of liver cirrhosis and hepatocellular 
carcinoma (HCC) worldwide. However, there is a lack of data regarding the epidemiology of CHC in Oman. This 
study aimed to describe the clinicopathological characteristics and outcomes of CHC-infected patients at a tertiary 
care hospital in Oman. Methods: This retrospective descriptive hospital-based study included all CHC-infected 
patients who presented to the Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, between January 
2010 and December 2015. The baseline demographic, clinical, laboratory and radiological data of the patients were 
analysed. Results: A total of 603 CHC-infected patients were identified during the study period; of these, 65.8% 
were male and the mean age was 44.8 ± 16.5 years. The main risk factors associated with CHC infection were 
intravenous drug abuse (23.9%) and a history of blood transfusions (20.7%). The most prevalent virus genotypes 
were 1 and 3 (44.0% and 35.1%, respectively). Upon initial presentation, 33.0% of the cohort had liver cirrhosis; of 
these, 48.7% had decompensated cirrhosis and 23.1% had HCCs. Liver transplantation was only performed for 7.5% 
of the cirrhosis patients, mostly as a curative treatment for HCC. Conclusion: The implementation of national 
policies to prevent hepatitis C transmission and encourage the early screening of at-risk patients is recommended 
to reduce the burden and consequences of this disease in Oman.
Keywords: Chronic Hepatitis C; Hepatocellular Carcinoma; Liver Cirrhosis; Infectious Disease Transmission; 
Genotypes; Oman.
بيانات  توجد  العامل.ل  اأنحاء  جميع  يف  الكبد  و�رشطان  لتليف  رئي�صيا  �صببا  ج  املزمن  الوبائي  الكبد  التهاب  يزال  ل  الهدف:  امللخ�ص: 
متاحة عن التهاب الكبد الوبائي املزمن ج يف عمان. هدفت هذه الدرا�صة اإىل و�صف اخل�صائ�ض املر�صية ونتائج املر�صى يف م�صت�صفى 
ومتابعتهم  تقييمهم  مت  الذين  ج  املزمن  الوبائي  الكبد  التهاب  مر�صى  جلميع  م�صتعر�صة  درا�صة  هذه  الطريقة:  عمان.  يف  ثالثية  رعاية 
الدميوغرافية وال�رشيرية  البيانات  2015. مت جمع وحتليل  اإىل دي�صمرب   2010 الفرتة من يناير  ال�صلطان قابو�ض يف  يف م�صت�صفى جامعة 
واملخربية والإ�صعاعية للمر�صى. النتائج: مت جمع بيانات 603 من املر�صى العمانيني امل�صابني بالفريو�ض الكبدي الوبائي ج املزمن. 
كان متو�صط اعمارهم 44.8 ± 16.5 �صنة وكانت ن�صبة الذكور منهم هي %65.8. وكانت العوامل الرئي�صية ل�صابة بالفريو�ض ج هي تعاطي 
املخدرات عن طريق الوريد ومثلت ن�صبة )%23.9( من املر�صى يليه وجود تاريخ مر�صي لنقل الدم من �صخ�ض لخر بن�صبة )%20.7(. وكان 
منط الفريو�ض اجليني الأكرث انت�صارا هو النمط 1 ثم النمط and 44.0%( 3 %35.1، على التوايل(. وجد تليف الكبد يف %33.0 من املر�صى، 
وعانى %48.7 منهم من عالمات الف�صل الكبدي بينما اأظهر %23.1 عالمات �رشطان الكبد. اأجريت عملية زرع الكبد يف %7.5 من مر�صى 
تليف الكبد ومع�صمهم كعالج ل�رشطان الكبد. اخلال�صة: هناك حاجة ما�صة اإىل تطبيق �صيا�صات وطنية منا�صبة للوقاية من انتقال التهاب 
الكبد الوبائي ج، والفح�ض املبكر للمر�صى املعر�صني خلطر الأ�صابة بالفريو�ض يف عمان للحد من عبء املر�ض وعواقبه.
الكلمات املفتاحية: التهاب الكبد الوبائي املزمن ج؛ الأمناط اجلينية؛ �رشطان الكبد؛ تليف الكبد؛ اإنتقال العدوى؛ عمان.
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Advances in Knowledge 
- To the best of the authors’ knowledge, the current study is the first to describe the clinical characteristics, risk factors, genotypes and 
outcomes of chronic hepatitis C (CHC)-infected patients in Oman. 
- In the current study, CHC-infected patients who were diagnosed based on existing evidence of liver disease had a higher prevalence of 
cirrhosis and hepatocellular carcinoma compared to patients who were diagnosed as a result of routine screening.
Application to Patient Care
- The results of this study emphasise the importance of implementing national policies for preventing the transmission of the hepatitis C 
virus in Oman. Early screening of at-risk patients and prompt management will help to reduce the burden of this disease.
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Currently, the hepatitis c virus (hcv) infects approximately 177–185 million indivi-duals worldwide.1 Chronic hepatitis C (CHC) 
infection is a gradual progressive disease characterised 
by persistent hepatic inflammation. It leads to the 
development of cirrhosis in approximately 20–30% 
of patients over 15–25 years; of those with cirrhosis, 
1% subsequently develop hepatocellular carcinoma 
(HCC) every year.1,2 With the recent development 
of oral direct-acting antiviral agents, the elimination 
of HCV within the next 15–20 years is predicted.1 
Unfortunately, liver cirrhosis and HCC rates are 
nevertheless expected to continue rising among HCV-
infected patients as many cases remain undiagnosed 
and risk factors go unrecognised.3,4 Screening prog-
rammes to enhance the early detection of infected 
patients and improve prevention strategies have been 
proven to reduce HCV-associated morbidity and 
mortality.5 Most patients with acute HCV infections 
remain asymptomatic; as such, progression to a chronic 
subclinical infection is very common. Usually, liver 
cirrhosis and other HCV-related complications occur 
approximately 20–30 years following HCV exposure.6 
In the absence of proper HCV screening, infected 
patients frequently present at a late stage with multiple 
complications.5–7 The presence of comorbidities like 
alcoholic liver disease, viral coinfection with HIV or 
hepatitis B and the presence of insulin resistance can 
further accelerate disease progression.8–11
In Oman, there are currently no national 
programmes in effect to promote public awareness, 
enhance early diagnosis or enable prompt management of 
CHC cases. In 1991, HCV testing was first introduced 
at the Sultan Qaboos University Hospital (SQUH), 
a tertiary referral hospital in Muscat, Oman.12 The 
estimated prevalence of anti-HCV-antibodies in Oman 
has been reported as 1% among healthy blood donors, 
41% among thalassaemic patients undergoing regular 
blood transfusions and 26.5% among patients on 
haemodialysis.12,13 However, more studies are needed 
to provide necessary information regarding HCV 
infection rates to policy-makers and health planners 
in Oman. This study therefore aimed to identify the 
clinical characteristics, risk factors and major clinical 
outcomes of CHC-infected patients at a tertiary care 
centre in Oman.
Methods
This retrospective descriptive hospital-based study 
was conducted at SQUH and included all patients with 
CHC infections presenting between January 2010 and 
December 2015. All CHC infections were diagnosed 
based on positive anti-HCV antibody and HCV ribo-
nucleic acid polymerase chain reaction test results. 
Patients were diagnosed with liver cirrhosis based on 
the presence of cirrhotic changes on an abdominal 
ultrasound scan, liver stiffness measurements of 
>12.5 kPa using a FibroScan® elastography device 
(Echosens™, Paris, France) within 12 months of 
inclusion in the study, a fibrosis-4 score of >3.25 or 
histopathological findings. Patients with acute HCV 
infections, incomplete records or those who were 
lost to follow-up were excluded from the study. The 
final sample was estimated to be representative of 
the national population. Information regarding the 
demographic and clinical characteristics, risk factors 
for HCV transmission, histological/radiological data 
and outcomes of the patients were subsequently 
collected from electronic hospital records.
Data were analysed using the Statistical Package 
for the Social Sciences (SPSS), Version 17.0 (IBM Corp., 
Armonk, New York, USA). Results were expressed 
as numbers and percentages for categorical variables 
and as means and standard deviations for continuous 
Table 1: Sociodemographic characteristics of chronic 
hepatitis C-infected patients at the Sultan Qaboos 





Mean ± SD 44.8 ± 16.5
Gender
Male 397 (65.8)
Female 206 (34.2) 
BMI in kg/m2*
<29.8 416 (79.5) 
>29.9 107 (20.5)







Alcohol consumption 103 (17.1)
Smoking 68 (11.3)
SD = standard deviation; BMI = body mass index.
*Total dataset for this variable was 523 as 80 patients with ascites were 
excluded.
Epidemiology of Chronic Hepatitis C Infections at a Tertiary Care Centre in Oman
e406 | SQU Medical Journal,  November 2017, Volume 17, Issue 4
variables. The relationships between genotype distrib- 
ution and age, place of residence and mode of trans-
mission were examined using a Chi-squared test. All 
statistical analyses were based on two-sided hypothesis 
tests with a significance level set at P <0.050.
This study was approved by the Medical Research 
& Ethics Committee of the College of Medicine & 
Health Sciences, Sultan Qaboos University (MREC 
#844). 
Results
A total of 603 patients with confirmed CHC infections 
presented to SQUH during the study period. The 
mean age of the patients was 44.8 ± 16.5 years (range: 
5–90 years old) and the majority were male (65.8%). 
Excluding 80 patients with ascites, 20.5% of the sample 
were classified as obese with a body mass index of 
>29.9 kg/m2. Alcohol consumption and smoking were 
reported by 103 (17.1%) and 68 (11.3%) patients, resp- 
ectively [Table 1]. Out of 569 patients with available 
data, 392 (68.9%) had identifiable HCV risk factors. 
The most commonly identified risk factors were 
intravenous drug abuse (23.9%) followed by blood 
transfusions (20.7%), most of which had been 
performed before 1991. Other risk factors included a 
history of surgery (5.1%), a family history of infection 
(7.2%), haemodialysis (4.2%) and organ grafting (2.1%) 
[Figure 1]. 
Overall, routine HCV testing was performed for 
290 patients (48.1%) based on standard indications, 
including for patients undergoing frequent blood 
transfusions and screening prior to invasive procedures 
or blood donations and as part of pre-employment 
conditions. Of the screened patients, 46 (15.9%) and 
11 (3.8%) had liver cirrhosis and HCC, respectively. 
On the other hand, 258 cases (42.8%) were diagnosed 
based on various liver disease-related findings (e.g. 
elevated liver enzymes, acute hepatitis or acute variceal 
bleeding). Within that subgroup, a higher proportion 
of patients with liver cirrhosis or HCC were identified 
(47.3% and 12.4%, respectively) [Figure 2].
The vast majority of patients (84.4%) were 
asymptomatic at the time of initial presentation. For 
symptomatic patients, dyspepsia (62.8%), fatigue 
(60.6%), abdominal pain (58.5%) and jaundice (26.6%) 
were the predominant symptoms reported. A total of 
55.6% of the patients had low viral loads. Most patients 
had at least one comorbidity, including hypertension 
(21.6%), diabetes (20.7%), anaemia (19.2%), renal 
impairment (13.6%) or cardiac conditions (13.1%). Co- 
infections with chronic hepatitis B or HIV was reported 
in 39.0% and 2.0% of patients, respectively. [Table 2]. 
The most prevalent HCV genotype was genotype 1 
(44.0%) followed by genotypes 3 (35.1%), 4 (15.0%), 2 
(3.7%) and mixed (2.2%). For intravenous drug abusers, 
the most common genotype was 3 (53.0%) followed by 
Figure 1: Risk factors for hepatitis C virus infection 
among chronic hepatitis C-infected patients at the 
Sultan Qaboos University Hospital, Muscat, Oman 
(N = 569).‡
IV = intravenous.
*Of these transfusions, 13.0% were performed before 1991. 
†Including extramarital relationships (1.7%), sharp needle stick 
injuries (0.5%) and tattooing (0.4%). ‡Total dataset for this 
variable was 569 as 34 patients were excluded due to missing data. 
Figure 2: Prevalence of liver cirrhosis and hepatocellular carcinoma among chronic hepatitis C-infected patients 
diagnosed as a result of (A) routine screening (n = 290) and (B) as a result of existing evidence of liver disease 
(n = 258) at the Sultan Qaboos University Hospital, Muscat, Oman (N = 548)*.
HCC = hepatocellular carcinoma.
*Total dataset for this variable was 548 as 55 patients were excluded due to missing data. 
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1 (40.9%). Among those with a history of blood trans- 
fusions, genotype 1 was the most prevalent (59.1%) 
followed by 3 (20.9%). There were significant assoc-
iations between genotype distribution and age, place 
of residence and mode of transmission (P <0.050 each) 
[Table 3].
A total of 199 patients (33.0%) had liver cirrhosis 
upon initial presentation. Of these, 97 (48.7%) had 
one or more features suggestive of hepatic decomp-
ensation, including portal hypertension, ascites, 
hypersplenism, hepatic encephalopathy, hepatorenal 
syndrome or hepatic hydrothorax. A total of 61 
patients with liver cirrhosis (30.7%) were diagnosed 
with HCC; among these cases, 27 (44.3%) had 
advanced HCC beyond the Milan criteria for liver 
transplantation.14 Only 15 cirrhosis patients (7.5%) 
underwent liver transplantation, for which the most 
common indication was as therapeutic management 
for early-stage HCC (n = 8; 53.3%) [Figure 3].
Discussion
Controlling HCV infections is of critical importance 
to prevent CHC progression and the subsequent 
development of decompensated cirrhosis and HCC. 
However, the asymptomatic nature of most CHC cases 
clearly limits this objective.15,16 Moreover, Oman has 
no community-based screening programme to target 
its high-risk population. To the best of the authors’ 
knowledge, the current study is the first to report the 
clinical characteristics and outcomes of CHC-infected 
patients in Oman. Overall, the findings indicated that 
most patients resided in the highly-populated Muscat 
and Al-Batinah governorates. Similar results have 
been reported in Western countries, with a greater 
prevalence of HCV in high-population compared to 
low-population communities, possibly due to the 
Table 2: Baseline clinical characteristics among chronic 
hepatitis C-infected patients at the Sultan Qaboos 





Abdominal pain 55 (58.5)
Jaundice 25 (26.6)
Nausea and vomiting 21 (22.3)







Renal impairment 82 (13.6)
Cardiac conditions 79 (13.1)
Dyslipidaemia 67 (11.1)
Psychological disorders 45 (7.5)
Autoimmune diseases 42 (7.0)
Sickle cell disease 40 (6.6)
Malignancies 35 (5.8)§
Neutropaenia¶ 33 (5.5)
Thalassaemia major 25 (4.1)
Haemophilia 5 (0.8)
Coinfections
Hepatitis B// 213 (39.0)
HIV** 10 (2.0)
HTN = hypertension; DM = diabetes mellitus.
*Total dataset for this variable was 94 as 509 asymptomatic patients 
were excluded. †Percentages for these variables add up to more than 
100% as some patients may have reported multiple symptoms/
comorbidities. ‡Defined as a haemoglobin level of <10 mg/dL. §Of these, 
six cases had lymphoma. ¶Defined as an absolute neutrophil count of 
<1,000. //Out of 546 patients who underwent hepatitis B core antibody 
testing. **Out of 494 patients who underwent HIV testing.
Table 3: Genotype distribution according to age, residence 
and mode of transmission among chronic hepatitis 
C-infected patients at the Sultan Qaboos University Hospital, 
Muscat, Oman (N = 539)*
Variable Total Genotype, n (%) P 
value
1 3 Other
































Abroad 27 6 
(22.2)
6 (22.2) 15 
(55.6)
Mode of transmission
















 *Total dataset for this variable was 539 as 64 patients were excluded due 
to missing genotype data. †Age of <50 years old.
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increased availability of illegal drugs.17 However, it 
is also possible that some patients living in other 
governorates in Oman were referred to other hospitals 
apart from SQUH during the study period.
Globally, the distribution of HCV genotypes 
differs according to epidemiological variations, includ-
ing differences in modes of transmission and ethnic 
and temporal factors.16 However, there is a paucity 
of data regarding the distribution of HCV genotypes 
in Oman. Al-Naamani et al. previously reported the 
genotype distribution of 33 multi-transfused β-thala-
ssaemia Omani patients to be 55%, 27%, 9% and 9% for 
genotypes 1, 4, 2 and 3, respectively.12 However, in the 
current study, genotype 1 was most prevalent (44.0%), 
followed by genotypes 3 (35.1%), 4 (15.0%), 2 (3.7%) 
and mixed (2.2%). This discrepancy in findings could 
be due to the fact that Al-Naamani et al.’s study focused 
purely on a subset of multi-transfused thalassaemic 
patients; these patients were most likely infected from 
transfused blood imported to Oman before 1991, 
when HCV screening first began.12 The prevalence of 
genotype 1 over other genotypes in the current study 
was similar to reports from other Middle Eastern 
countries like the United Arab Emirates (UAE; 49.2%), 
Turkey (95.6%), Iran (56.2%) and Bahrain (37%).18–21 
However, other studies from Saudi Arabia, Yemen and 
Iraq found that genotype 4 was most frequent.22–24
In the current study, alcohol and tobacco use 
were relatively uncommon. Nevertheless, alcohol 
consumption and smoking are well-known risk factors 
for disease progression to liver cirrhosis and HCC 
among CHC patients.25 Moreover, alcohol intake may 
be associated with other risky behaviours; as such, this 
factor should be considered a potential target for HCV 
screening.26 Almost half of the patients in the current 
cohort were first diagnosed with CHC based on 
existing evidence of liver disease, such as elevated liver 
enzymes, deranged liver function or imaging findings. 
Moreover, this subgroup of patients had a much 
higher prevalence of cirrhosis and HCC compared to 
asymptomatic patients who were diagnosed as a result 
of routine screening. This finding emphasises the 
importance of early HCV screening and diagnosis in 
high-risk populations; indeed, this may be especially 
effective in improving clinical outcomes coupled with 
the newfound availability of highly effective antiviral 
regimens.27
Nearly a quarter of the CHC patients in the 
present study were infected as a result of intravenous 
drug abuse; of these, the majority had genotypes 3 and 1. 
A similarly high prevalence of genotypes 3 and 1 
has been reported among intravenous drug users in 
France and the UAE.18,28 Blood transfusions were the 
second most common mode of HCV transmission 
in the current study, with genotypes 1 followed by 3 
being most prevalent among affected individuals. In 
contrast, Shahraki et al. found that genotype 3a (40%) 
was most prevalent among transfused thalassaemic 
patients in Iran, followed by genotype 1b (25%).29 
Critically, the findings of the current study indicate that 
blood transfusion is still a possible risk factor for HCV 
transmission in Oman despite the routine screening 
of transfused blood. This may be potentially due to the 
use of serological testing instead of advanced screening 
techniques such as nucleic acid amplification.30
A history of surgery is another risk factor for HCV 
infection due to the role that contaminated surgical 
equipment can play in the transmission of blood-borne 
Figure 3: Diagram showing the clinical outcomes* of chronic hepatitis C-infected patients presenting to the Sultan 
Qaboos University Hospital, Muscat, Oman (N = 603).
HCC = hepatocellular carcinoma; HTN = hypertension; HRS = hepatorenal syndrome; SBP = spontaneous bacterial peritonitis.
*Percentages for some outcomes add up to more than 100% as some patients may have reported multiple outcomes.
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diseases. The incidence of surgery-associated HCV 
infections caused by breaches in infection control 
practices have been previously reported in the USA.31 
In the current study, many of the surgeries reported 
by CHC patients were performed before routine HCV 
screening was initiated prior to invasive surgeries. 
In addition, many of the surgeries were carried out 
abroad; as such, adherence to blood-borne pathogen 
screening protocols at such institutions was unknown. 
Therefore, public awareness of the importance of 
presurgical HCV screening should be increased in 
Oman; in addition, local infection control policies and 
procedures at governmental hospitals should be 
reviewed to ensure that surgical equipment is adequ-
ately disinfected.
Approximately one-third of the patients in the 
present study did not report any risk factors for 
HCV, which is similar to other findings reported in 
the literature.32 This suggests the presence of other 
unidentified modes of HCV transmission in Oman, 
such as traditional healers, body piercings, barber 
shops and professional pedicures/manicures. Another 
important finding was that many HCV-infected 
patients in the current study also had advanced liver 
disease, including decompensated cirrhosis and HCC; 
moreover, many of the HCC cases were beyond the 
Milan transplantation criteria.14 This prevalence of 
advanced HCV-related complications upon present-
ation is high in comparison to other research.27 Further 
studies are therefore needed to assess risk factors for 
cirrhosis and HCV-related outcomes among Omani 
patients. The current study also showed a low rate of 
liver transplantation amongst CHC-infected patients 
with decompensated cirrhosis. Since Oman does not 
have a liver transplant service, candidates are usually 
sent abroad for the procedure as long as they can 
find a willing and compatible living adult donor. The 
generalisability of the results of the current study was 
limited by the retrospective nature of the study and 
the fact that participants were selected from a single 
tertiary health care facility. 
Conclusion
In the current study, major risk factors for HCV 
transmission included intravenous drug abuse and 
blood transfusions, with genotypes 1 and 3 being most 
frequent. Moreover, patients diagnosed with CHC via 
routine screening had lower morbidity compared to 
patients who were only diagnosed as a result of existing 
signs of liver disease. Therefore, the implementation 
of national policies to prevent HCV transmission and 
encourage the early screening of at-risk individuals 
and prompt management of HCV cases is highly 
recommended. In addition, more studies are needed 
to understand the prevalence of and risk factors for 
poor HCV-related outcomes in Oman.
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